SCHEMBL7178530

SCHEMBL7178530

O=CNC1CCC(n2c(=O)[nH]c3cc(C(F)(F)F)cnc32)CC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.39
JAK3 P52333 5/20 0.39
TNKS O95271 3/20 0.36
DGAT1 O75907 1/20 0.36
HSD11B1 P28845 2/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TNKS2 Q9H2K2 1/20 0.35
KCNH2 Q12809 1/20 0.35
OPRM1 P35372 2/20 0.35
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
JAK1 P23458 3/20 0.34
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
NR5A2 O00482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7178523 1.00 JAK2 (0.39) JAK2JAK3TNKSDGAT1HSD11B1
SCHEMBL7191692 0.84 ALDH1A1 (0.49) JAK2JAK3HSD11B1ALDH1A1SMN1; SMN2
SCHEMBL7183957 0.80 ALDH1A1 (0.56) JAK2JAK3TNKSDGAT1HSD11B1
SCHEMBL7183953 0.80 ALDH1A1 (0.56) JAK2JAK3TNKSDGAT1HSD11B1
SCHEMBL7180238 0.77 HSD11B1 (0.39) JAK2JAK3TNKSHSD11B1ALDH1A1
SCHEMBL7180232 0.77 HSD11B1 (0.39) JAK2JAK3TNKSHSD11B1ALDH1A1
SCHEMBL21811053 0.74 HSD11B1 (0.45) JAK2JAK3TNKSHSD11B1KCNH2
SCHEMBL21811052 0.74 HSD11B1 (0.45) JAK2JAK3TNKSHSD11B1KCNH2
SCHEMBL7183866 0.69 HSD11B1 (0.47) HSD11B1
SCHEMBL16593900 0.69 MEN1 (0.61) SMN1; SMN2KCNH2CYP2C9CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed